Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 3, 2006, Pages 149-157

  Sasaki, Hidehisa ^a   Kanai, Saburo ^a   Oyama, Tomokazu ^a   Miyashita, Yoh ^a   Yamamura, Shigeo ^b   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Benidipine hydrochloride; Elderly; Hypertensive diabetic patient; Preheparin serum lipoprotein lipase mass

Indexed keywords

BENIDIPINE; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIHYDROPYRIDINE DERIVATIVE; HEPARIN; LIPID; LIPOPROTEIN LIPASE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DIASTOLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; SYSTOLE;

AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIASTOLE; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; HYPERTENSION; LIPID METABOLISM; LIPIDS; LIPOPROTEIN LIPASE; MALE; SYSTOLE; TETRAZOLES;

EID: 33749077567     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.149     Document Type: Article

References (34)

1. Hiwada K, Ogihara T, Morimoto S, Matsumoto M, Iwai K, Takasaki M, Matsuoka H, Takishita S, Kawano Y, Shimamoto K, Higashiura K, Toba K, Kozaki K, Eto M, Abe I, Fujishima M, Kohara K, and Mikami H: Guidelines on treatment of hypertension in the elderly 1999 revised version. A comprehensive study on geriatric science by the ministry of health and welfare. A section for the "Study on long-term prognosis of hypertension among the aged". Nippon Ronen Igakkai Zasshi, 1999; 27:576-603.
2. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, Wilson PW. Rifai N, Meigs JB, Ricken G, Lifton RP, Levy D, and Vasan RS: Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens, 2005; 18:657-665.
3. Mitchell GF, Parise H, Vita JA, Larson MG, Warner E, Keaney JF Jr, Keyes MJ, Levy D, Vasan RS, and Benjamin EJ: Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension, 2004; 44:134-139.
4. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, and Levy D: Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension, 2004; 43:1239-1245.
5. Nawrot TS, Staessen JA, Thijs L, Fagard RH, Tikhonoff V, Wang JG, and Franklin SS: Should pulse pressure become part of the Framingham risk score? J Hum Hypertens, 2004; 18:279-286.
6. Piechowski JB and Bogousslavsky J: Antihypertensive and lipid lowering treatment in stroke prevention: current state and future. Acta Neurol Belg, 2005; 105:57-61.
7. Okada K, Hirano T, Ran J, and Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res, 2004; 27:293-299.
8. Feingold KR, Grunfeld C, Pang M, Doerrler W, and Krauss RM: LDL subclass phenotypesand triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb, 1992; 12:1496-1502.
9. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, and Yoshida S: Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chem Acta, 1993; 216:113-123.
10. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, and Watanabe H: Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterol. J Clin Lab Anal, 1997; 11:82-86.
11. Burstein M, Scholnick HR, and Morfin R: Rapid method for the isolation of lipoprotein from human serum by precipitation with polyanions. J Lipid Res, 1970; 11:583-595.
12. Mishima Y, Ando M, Kuyama A, and Kibata Y: A simple method for identifying particle size of low-density lipoprotein using PAG Tm electrophoresis; Comparison between LipoPhorTM and LipoPrint LDL™ systems. J Jpn Atheroscler, 1997; 25:67-70.
13. Totsuka M, Miyashita Y, Itoh Y, Watanabe H, and Shirai K: Properties of fast 13 lipoprotein on the PAG disc electrophoresis and its role in diabetic complications. J Jpn Diabetes Soc, 1997; 40:503-511.
14. Tornvall P, Olivercrona G, Carpe F, Andres H, and Olivecrona T: Lipoprotein lipase mass and activity in plasma and there increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15:1086-1093.
15. Hirano T, Nishioka F, and Murakami T: Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism, 2004; 53:526-531.
16. Miyashita Y, Ito Y, Hasiguchi S, Totsuka M, Aoki A, Kurokawa M, Tomioka H, and Shirai K. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J Atheroscler Thromb, 2001; 8:25-29.
17. Coresh J, Kwiterovich PO, Smith HH, and Bachorik PS: Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res, 1993; 34:1687-1697.
18. Ginsberg FIN, Zang YL, and Hernandez OA. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res, 2005; 36:232-240.
19. Pontrelli L, Parris W, Adeli K, and Cheung RC: Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism, 2002; 51:334-342.
20. Reaven GM, Chen YD, Jeppesen J, Maheux P, and Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clinical Invest, 1993; 992:141-146.
21. Watanabe H, Shirai K, Murano T, Hiroh Y, Itoh Y, and Miyashita Y: Preheparin serum lipoprotien lipase mass level: The effects of age, gender, and types of hyperlipidemias. Atherosclerosis, 1999; 145:45-50.
22. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano H, Watanabe H, and Miyashita Y: The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diab Res Clin Prac, 1999; 46:35-41.
23. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, and Watanabe H: Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diab Res Clin Prac, 2002; 56:181-187.
24. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, and Saito Y: Pre-heparin plasma lipoprotein lipase mass: its correlation with intra-abdominal visceral fat accumulation. Horm Metab Res, 2001; 33:412-416.
25. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, and Shirai K: Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis, 2000; 153:391-396.
26. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneda S, Hirayama S, Suzuki K, Nakamura Y, Yamatani K, and Aizawa Y: Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis, 2004; 174:385-390.
27. Miyashita Y and Shirai K: Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. Curr Med Chem Cardiovasc Hematol Agents, 2005; 3:377-381, Review.
28. Wong ND, Pio JR, Franklin SS, L'Italin GJ, Kamath TV, and Williams GR: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol, 2003; 91:1421-1426.
29. Part MR, Yanek LR, Moy TF, and Becker DM: Assessment of global coronary heart disease risk in overweight and obese African-American women. Obes Res, 2003; 11:660-667.
30. Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens, 2000; 13:3S-10S.
31. Grassi G, Dell'Oro R, Quarti TF, Scopelliti F, Seravalle G, Paleari F, Gamba. PL, and Mancia G: Neuroadrenegic and reflex abnormalities in patients with metabolic syndrome. Diabetologia, 2005; 49:1359-1365.
32. Rosolova H: The sympathetic nervous system and insulin resistance. Vnitr Lek, 2003; 49:61-65.
33. Quillot D, Fluckiger L, Zannad F, Drouin P, and Ziegler O: Impaired autonomic control of heart rate and blood pressure in obesity: role of age and insulin-resistance. Clin Anton Res, 2001; 11:79-86.
34. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, and Scherrer U: Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest, 1994; 93:2365-2371.